Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 70 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC)	Canakinumab (Ilaris; ACZ885) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer	Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2022	View \| Download
Enfortumab vedotin with pembrolizumab for treating bladder cancer	Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2023	View \| Download
Lenvatinib and pembrolizumab with transarterial chemoembolisation for treating hepatocellular carcinoma	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Lenvatinib in addition to everolimus or pembrolizumab for advanced renal cell carcinoma – First line	Everolimus (Zortress; RAD001; Afinitor; Certican; RAD-001) , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Lenvatinib in combination with pembrolizumab for advanced endometrial cancer – second line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2020	View \| Download
Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer - First Line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2021	View \| Download
Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Head and neck cancer , Squamous cell carcinoma (SCC)	Head and Neck Cancer	2022	View \| Download